Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409561 · ClinicalTrials.gov registry record
Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population
A clinical trial of Healthy and Sepsis, sponsored by Abionic.
- Completed
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04409561: Completed study of Healthy and Sepsis, sponsored by Abionic.
NCT04409561 is a study of Healthy and Sepsis that has completed, run by Abionic. The registered enrollment target is 150 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409561, a study of Healthy and Sepsis, has completed, sponsored by Abionic.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.
Primary Outcome
To determine the reference range intervals of PSP values measured using abioSCOPE device with the PSP assay in a generally healthy population representative of the US population.
Conditions Studied
Interventions
- DEVICE Blood collection
Study Locations (1)
Ohio
- Mercy Health St. Vincent - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2022-01-15 |
What the finished NCT04409561 record still lists
NCT04409561 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Blood collection is the first listed.
NCT04409561 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04409561 about?
NCT04409561 is a clinical study titled "Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population". This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.
What is the current status of trial NCT04409561?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2021-11-15. Estimated completion is 2022-01-15.
What conditions does trial NCT04409561 study?
This clinical trial studies the following conditions: Healthy, Sepsis, Septic Shock.
What interventions are being tested in trial NCT04409561?
The interventions under investigation include: Blood collection (DEVICE).
Who is sponsoring clinical trial NCT04409561?
This trial is sponsored by Abionic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04409561 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04409561's enrollment target sits among peer trials
150 152nd of 1090 higher than 935 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI